Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer
- Hossein Borghaei
- , Scott Gettinger
- , Everett E. Vokes
- , Laura Q.M. Chow
- , Marco Angelo Burgio
- , Javier de Castro Carpeno
- , Adam Pluzanski
- , Oscar Arrietac
- , Osvaldo Arén Frontera
- , Rita Chiari
- , Charles Butts
- , Joanna Wójcik-Tomaszewska
- , Bruno Coudert
- , Marina Chiara Garassino
- , Neal Ready
- , Enriqueta Felip
- , Miriam Alonso García
- , David Waterhouse
- , Manuel Domine
- , Fabrice Barlesi
- Yale University
- University of Chicago
- University of Washington
- IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
- Hospital de Madrid
- Maria Sklodowska-Curie Institute of Oncology
- Instituto Nacional de Cancerologia - Mexico
- Centro Internacional de Estudios Clinicos
- University Hospital of Perugia
- Cross Cancer Institute
- Provincial Center of Oncology in Gdansk
- Georges François Leclerc Cancer Center
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Duke University
- Vall d'Hebron Institute of Oncology
- Hospital Universitario Virgen del Rocio
- Oncology Hematology Care Inc
- Hospital Universitario Puerta de Hierro Majadahonda
- Aix-Marseille University
- University of South Florida
- Robert Bosch Cancer Center
- University of Texas Southwestern Medical Center
- John Paul II Hospital, Krakow
- Sarah Cannon Research Institute
- University Hospital and Ruhrlandclinic
- Bristol-Myers Squibb
- Johns Hopkins University
Research output: Contribution to journal › Article › peer-review
600
Scopus
citations